<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>D-C-P016-107R</udiDi>
    <basicUdiDi>B-C-P016-107R</basicUdiDi>
    <tradeName>Podoplanin (QR048)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription></emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P016-10</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:32.153Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P017-017X</udiDi>
    <basicUdiDi>B-C-P017-017X</basicUdiDi>
    <tradeName>p21 (QR085)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P017-01</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.624Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P017-025RU</udiDi>
    <basicUdiDi>B-C-P017-025RU</basicUdiDi>
    <tradeName>p21 (QR085)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P017-025</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.599Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P017-0587</udiDi>
    <basicUdiDi>B-C-P017-0587</basicUdiDi>
    <tradeName>p21 (QR085)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P017-05</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.579Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P017-107Y</udiDi>
    <basicUdiDi>B-C-P017-107Y</basicUdiDi>
    <tradeName>p21 (QR085)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P017-10</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.555Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P019-018D</udiDi>
    <basicUdiDi>B-C-P019-018D</basicUdiDi>
    <tradeName>PAX2 (QR060)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P019-01</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.537Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P019-025SJ</udiDi>
    <basicUdiDi>B-C-P019-025SJ</basicUdiDi>
    <tradeName>PAX2 (QR060)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P019-025</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.520Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P019-058M</udiDi>
    <basicUdiDi>B-C-P019-058M</basicUdiDi>
    <tradeName>PAX2 (QR060)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P019-05</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.498Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P019-108E</udiDi>
    <basicUdiDi>B-C-P019-108E</basicUdiDi>
    <tradeName>PAX2 (QR060)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P019-10</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.477Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P020-016R</udiDi>
    <basicUdiDi>B-C-P020-016R</basicUdiDi>
    <tradeName>PAX5 (QR056)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P020-01</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.455Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P020-025PU</udiDi>
    <basicUdiDi>B-C-P020-025PU</basicUdiDi>
    <tradeName>PAX5 (QR056)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P020-025</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.433Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P020-056Z</udiDi>
    <basicUdiDi>B-C-P020-056Z</basicUdiDi>
    <tradeName>PAX5 (QR056)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P020-05</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.414Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P020-106S</udiDi>
    <basicUdiDi>B-C-P020-106S</basicUdiDi>
    <tradeName>PAX5 (QR056)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P020-10</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.392Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P021-016Y</udiDi>
    <basicUdiDi>B-C-P021-016Y</basicUdiDi>
    <tradeName>PLAP (QR084)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P021-01</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.370Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P021-025Q7</udiDi>
    <basicUdiDi>B-C-P021-025Q7</basicUdiDi>
    <tradeName>PLAP (QR084)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P021-025</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.340Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P021-0578</udiDi>
    <basicUdiDi>B-C-P021-0578</basicUdiDi>
    <tradeName>PLAP (QR084)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P021-05</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.305Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P021-106Z</udiDi>
    <basicUdiDi>B-C-P021-106Z</basicUdiDi>
    <tradeName>PLAP (QR084)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P021-10</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.265Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P022-0177</udiDi>
    <basicUdiDi>B-C-P022-0177</basicUdiDi>
    <tradeName>PSMA (QR079)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P022-01</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.232Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P022-025QJ</udiDi>
    <basicUdiDi>B-C-P022-025QJ</basicUdiDi>
    <tradeName>PSMA (QR079)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P022-025</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.213Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-C-P022-057F</udiDi>
    <basicUdiDi>B-C-P022-057F</basicUdiDi>
    <tradeName>PSMA (QR079)</tradeName>
    <deviceName></deviceName>
    <manufacturerName>biocyc Biotechnologie GmbH &amp; Co. KG</manufacturerName>
    <manufacturerSrn>DE-MF-000031533</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Genel</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>PRIMARY ANTISERA FOR IMMUNOHISTOLOGY</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>C-P022-05</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:11:25.187Z</lastUpdated>
  </row>
</eudamedExport>